Clinical Trial Update: Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating copanlisib in persistent or recurrent endometrial cancer has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Endometrioid Adenocarcinoma
• Endometrial Mixed Cell Adenocarcinoma
• Endometrial Serous Adenocarcinoma
• Endometrial Undifferentiated Carcinoma
• Endometrioid Adenocarcinoma
• Uterine Corpus Cancer

Drugs mentioned

• Copanlisib (copanlisib)

Snippet

Sponsor: NRG Oncology | Conditions: Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2020-03-06